Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.

• Status: Unknown status
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the effects of rapid escalation of Cabergoline in comparison to conventional dosing in macroprolactinomas. Rapid escalation of cabergoline may help in earlier normalization of prolactin and shrinkage of tumor mass, and thus decrease the cumulative dose of cabergoline altogether.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Cabergoline; Dopamine; Dopamine Agonists

Criteria

Inclusion Criteria:

Males or females presenting with

1. Prolactin secreting macroadenomas (≥10 mm maximum diameter)

2. With/without visual complaints

3. With /without parasellar or suprasellar extension

4. Treatment Naïve

Exclusion Criteria:

1. On treatment with dopamine agonists.

2. Taking other drugs influencing prolactin Levels.

3. Systemic disease like Chronic Kidney Disease, Chronic Lung Disease

4. Other secondary causes of hyperprolactinemia.

5. Prolactin secreting microadenomas

6. Pregnancy during follow up

7. Prolactinoma as part of MEN-1 Syndrome

8. History suggestive of recent apoplexy (3 months)

9. Contraindication to cabergoline therapy like pre existing psychosis.